Washington · statute · Wash. Rev. Code ch. 43.71C · 17 active provisions
The definitions in this section apply throughout this chapter unless the context clearly requires otherwise.(1) "340B drug" means a drug that has been subject to an offer for reduced prices by a manufacturer under 42 U.S.C. Sec. 256b and is purchased by a covered entity.(2) "Authority" means the health care authority.(…
Beginning October 1, 2019, and on a yearly basis thereafter, a health carrier must submit to the authority the following prescription drug cost and utilization data for the previous calendar year for each health plan it offers in the state:(1) The twenty-five prescription drugs most frequently prescribed by health care…
(1) By March 1st of each year, a pharmacy benefit manager must submit to the authority the following data from the previous calendar year:(a) All discounts, including the total dollar amount and percentage discount, and all rebates received from a manufacturer for each drug on the pharmacy benefit manager's formularies…
(1) No later than March 1st of each calendar year, each pharmacy benefit manager must file with the authority, in the form and detail as required by the authority, a report for the preceding calendar year stating that the pharmacy benefit manager is in compliance with this chapter.(2) A pharmacy benefit manager may not…
(1) Beginning October 1, 2019, a covered manufacturer must submit to the authority the following data for each covered drug:(a) A description of the specific financial and nonfinancial factors used to make the decision to set or increase the wholesale acquisition cost of the drug. In the event of a price increase, a co…
(1) Beginning October 1, 2019, a manufacturer must submit written notice, in a form and manner specified by the authority, informing the authority that the manufacturer has filed with the FDA:(a) A new drug application or biologics license application for a pipeline drug; or(b) A biologics license application for a bio…
(1) Beginning October 1, 2019, a manufacturer of a covered drug must notify the authority of a qualifying price increase in writing at least sixty days prior to the planned effective date of the increase. The notice must include:(a) The date of the increase, the current wholesale acquisition cost of the prescription dr…
(1) Beginning October 1, 2019, and on a yearly basis thereafter, a pharmacy services administrative organization representing a pharmacy or pharmacy chain in the state must submit to the authority the following data from the previous calendar year:(a) The negotiated reimbursement rate of the twenty-five prescription dr…
The authority may assess a fine of up to $1,000 per day for failure to comply with the requirements of RCW 43.71C.020 through 43.71C.080 and RCW 43.71C.130 and 43.71C.140. The assessment of a fine under this section is subject to review under the administrative procedure act, chapter 34.05 RCW. Fines collected under th…
(1)(a) The authority shall compile and analyze the data submitted by health carriers, pharmacy benefit managers, manufacturers, and pharmacy services administrative organizations pursuant to this chapter and prepare an annual report for the public and the legislature synthesizing the data to demonstrate the overall imp…
The authority may adopt any rules necessary to implement the requirements of this chapter.
Information collected pursuant to this chapter may be shared with the health care cost transparency board established under chapter 70.390 RCW, subject to the same disclosure restrictions applicable under this chapter.
(1) Annually, on or before April 1st following the conclusion of the covered entity's fiscal year, a covered entity located in Washington that is a federally qualified health center as defined in 42 U.S.C. Sec. 1396d(l)(2)(B) or a hospital defined in 42 U.S.C. Sec. 256b(a)(4)(L) through (O) shall report the following i…
(1) For manufacturers and covered entities required to report 340B data to the authority under RCW 43.71C.130 and 43.71C.050, the authority may establish a filing fee to support costs to administer the 340B data collection and reporting required by this chapter.(2) The filing fee shall be set by the authority at a leve…
The 340B program reporting account is created in the state treasury. All receipts from filing fees collected pursuant to RCW 43.71C.140 must be deposited into the account. Moneys in the account may be spent only after appropriation. Expenditures from the account may be used only by the authority and only for collecting…
The authority must contact the California office of statewide health planning and development and the Oregon department of consumer and business services to develop strategies to reduce prescription drug costs and increase prescription drug cost transparency. The authority must make recommendations to the legislature f…
The legislature finds that the state of Washington has substantial public interest in the following:(1) The price and cost of prescription drugs. Washington state is a major purchaser through the department of corrections, the health care authority, and other entities acting on behalf of a state purchaser;(2) Enacting…